Non-Insured Health Benefits Program (NIHB)
FIRAZYR is covered by the Non-Insured Health Benefits (NIHB) Program provided patient meets coverage criteria
Eligibility
For FIRAZYR to be eligible for coverage by the Non-Insured Health Benefits Program (NIHB), prescribers must submit a limited use benefit request form and approval must be in place before the patient fills the prescription. For more information concerning the reimbursement process, contact OnePath®.
Reimbursement Criteria
We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in Nunavut for your hereditary angioedema (HAE) patients who meet the following criteria:
Limited use benefit (prior approval required).
For the treatment of acute attacks of hereditary angioedema (HAE) in adults with lab confirmed C1-esterase inhibitor deficiency (type I or type II) and:
- Treatment of acute non-laryngeal attacks of at least moderate severity, OR
- Treatment of acute laryngeal attacks, AND
- Prescribed by a physician with experience in the treatment of HAE
Note: Limited to two (2) doses of prefilled syringes per dispense
OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.
Source: Non-Insured Health Benefits Program: Drug Benefit List. September 2020.
https://www.sac-isc.gc.ca/DAM/DAM-ISC-SAC/DAM-HLTH/STAGING/texte-text/nihb_benefits-services_drugs_dbl-index_1573154657223_eng.pdf